Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HC-1119 |
| Synonyms | |
| Therapy Description |
HC-1119 is a deuterated version of enzalutamide that inhibits androgen receptor (AR) by blocking its nuclear translocation and DNA-binding activity, which potentially results in enhanced apoptosis and reduced growth of AR expressing tumor cells (Journal of Clinical Oncology 2018 36:15_suppl, e17021; NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HC-1119 | HC 1119|HC1119|D3-ENT|Deuterated Enzalutamide|N-trideuteromethyl Enzalutamide | Hormone - Anti-androgens 57 | HC-1119 is a deuterated version of enzalutamide that inhibits androgen receptor (AR) by blocking its nuclear translocation and DNA-binding activity, which potentially results in enhanced apoptosis and reduced growth of AR expressing tumor cells (Journal of Clinical Oncology 2018 36:15_suppl, e17021; NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03850795 | Phase III | Enzalutamide HC-1119 | HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Terminated | USA | POL | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CAN | AUT | AUS | 1 |